🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Cold plunges are gaining popularity for their reported benefits, from reducing inflammation to aiding muscle recovery and boosting mood. The positive effects are numerous — but can cold plunges prevent or treat cancer? Learn what the research says: bit.ly/4dAiuRW

SERENA-6 Introduces Potential New Paradigm of Early ESR1 Mutation Detection to Delay Progression in HR+ Breast Cancer Erica Mayer Dana-Farber Harvard Medical School ASCO #ASCO25 #bcsm #oncology onclive.com/view/serena-6-…

Congratulations to Dana-Farber’s Judith Agudo who has been named a 2025 CRI Lloyd J. Old STAR by Cancer Research Institute for her innovative contributions to the field of cancer immunotherapy.

ADCs are rapidly improving the way we treat every type of cancer. Their potential has been largely unleashed over the past 6 years— yet their technology is the result of a 100-year long, epic journey. Join Raffaele Colombo & me to uncover 10 milestones in the development of ADCs (🧵):

Dana-Farber’s Breast Oncology Center - Join the webinar to learn about the intersection of aging and Metastatic Breast Cancer Dana-Farber’s Breast Oncology Center Dana-Farber Rachel Freedman, MD, MPH oncodaily.com/blog/312963 #OncoDaily #Oncology #Cancer #Health #Medicine

Dr. Sara Tolaney (Sara Tolaney) discusses findings from the phase III ASCENT-04/KEYNOTE-D19 study, which compared #SacituzumabGovitecan + #Pembrolizumab vs chemotherapy plus pembrolizumab in previously untreated patients with #PDL1–positive advanced #TripleNegativeBreastCancer

Register for the “Breast Cancer: New Horizons, Current Controversies” Course on July 17-18 – Dana-Farber’s Breast Oncology Center Dana-Farber’s Breast Oncology Center Harvard Medical School oncodaily.com/blog/breast-ca… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews #breastcancer

Woohoo!! Today the FDA announced FAST TRACK DESIGNATION for the PARP1-selective agent #DSB2455 from Duke Street Bio for patients with BRCA-associated triple negative breast cancer with brain metastases! So proud to be part of this team, where my lab Brigham and Women’s Department of Surgery and

A new first-line option for metastatic disease. A long awaited goodbye to carbo for stage II disease. A prospective confirmation for the role of HER2DX. And so much more evolution for the HER2+ disease at #ASCO25. Thanks OncLive.com for allowing me to review these terrific data.

This recent article describes Dana-Farber's Program for Older Adults with #BreastCancer sharing the successes, challenges, and next steps of a program uniquely focused on #OlderAdultsWithBreastCancer. 👉pubmed.ncbi.nlm.nih.gov/40334361/ ✍️Karen Ruderman DocHshieh Rachel Freedman, MD, MPH

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing

Register today for this free Ellie Fund Annual #BreastCancer Equity Symposium on self-advocacy and self-care. 🗓️Monday, June 23 ⏰ 2:00 - 6:00 PM 📍Roxbury Community College, Boston, MA Register: elliefund.org/events/

“They’ve thought of everything here - acupuncture, massage, meditation, the expressive arts.” The Boston Globe’s Stan Grossfeld reports from the Leonard P. Zakim Center for Integrative Therapies and Healthy Living Dana-Farber: bostonglobe.com/2025/06/17/met…

Understanding the Importance of the DESTINY-Breast09 Trial in HER2+ Breast Cancer Sara Tolaney Dana-Farber Dana-Farber’s Breast Oncology Center ASCO #ASCO35 #bcsm #BreastCancerAwareness curetoday.com/view/understan…

Don't miss this study in JCI insight showing #Imlunestrant, a next-generation oral #SERD, overcoming #ESR1 mutant resistance in estrogen receptor-positive #BreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/40327396/ Agostina Nardone Capucine Héraud Sheheryar Kabraji Sandro Santagata Sean Fanning Rinath Jeselsohn

T-DXd has shown tremendous activity in trials. But how does it perform in the real world? What is its activity in pts with BRCA+, PDL1+ dz, or prior SG? We joined forces with Yale University to address this question in one of the largest studies to date (n=~1500).🧵 esmoopen.com/article/S2059-…

Such a strong signal for our new partnership with BIDMC. You just got the best breast surgeon to lead the Program!

Congratulations Paolo Tarantino!

Congratulations, Dr. E Mittendorf!

The #SATEENtrial led by Dana-Farber’s Breast Oncology Center is a multi-center, single-arm phase II trial to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab for HER2+ #MetastaticBreastCancer. For more information call 877-338-7425 or visit: classic.clinicaltrials.gov/ct2/show/NCT06…